Top Page
Ramsay Health Care
(Sydney:RHC)
Ramsay Health Care (RHC) vs. iShares MSCI Australia ETF (EWA)
Ramsay Health Care Business Overview & Revenue Model
Ramsay Health Care Financial Statement Overview
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 17.79B | 17.79B | 16.66B | 14.96B | 13.08B | 12.86B |
| Gross Profit | 2.12B | 2.12B | 1.61B | 1.27B | 9.97B | 1.59B |
| EBITDA | 1.59B | 1.59B | 1.81B | 1.78B | 1.61B | 1.80B |
| Net Income | 24.00M | 24.00M | 888.70M | 298.10M | 274.00M | 449.00M |
Balance Sheet | ||||||
| Total Assets | 22.48B | 22.48B | 20.89B | 21.03B | 19.47B | 19.32B |
| Cash, Cash Equivalents and Short-Term Investments | 785.60M | 785.60M | 662.30M | 656.10M | 314.20M | 1.00B |
| Total Debt | 12.16B | 12.16B | 10.94B | 11.89B | 10.70B | 10.55B |
| Total Liabilities | 16.77B | 16.77B | 15.37B | 16.21B | 14.95B | 14.77B |
| Stockholders Equity | 5.02B | 5.02B | 4.90B | 4.15B | 3.93B | 4.03B |
Cash Flow | ||||||
| Free Cash Flow | 704.20M | 704.20M | 539.00M | 558.70M | 7.00M | 852.30M |
| Operating Cash Flow | 1.48B | 1.48B | 1.29B | 1.28B | 715.50M | 1.48B |
| Investing Cash Flow | -777.40M | -765.30M | 159.70M | -713.80M | 30.00M | -2.50B |
| Financing Cash Flow | -631.20M | -631.20M | -1.45B | -242.40M | -1.41B | 584.00M |
Ramsay Health Care Technical Analysis
Ramsay Health Care Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
71 Outperform | AU$520.92M | 15.80 | 18.59% | 4.60% | 6.73% | 37.16% | |
64 Neutral | AU$11.07B | 20.94 | 6.32% | 4.69% | 9.44% | -0.37% | |
56 Neutral | AU$2.08B | 42.40 | ― | 2.30% | 14.61% | ― | |
55 Neutral | AU$947.23M | 167.11 | 0.94% | 2.65% | 33.54% | ― | |
54 Neutral | $8.12B | 1,194.26 | 0.38% | 2.25% | 6.82% | -99.27% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
50 Neutral | AU$707.98M | -1.35 | -67.21% | ― | -23.02% | 33.11% |
Ramsay Health Care Corporate Events
Ramsay Health Care has agreed to acquire the assets and operations of National Capital Private Hospital in Garran, Canberra, from Healthscope Group entities for a net price of $251 million, funded through its existing debt facilities. The strategically located hospital, co-located with Canberra Hospital and adjacent to the Australian National University Medical School, has 8 theatres, a cath lab, 148 beds, an ICU and coronary care unit, and operates on a long-term lease with Canberra Health Services extending to 2064. Ramsay expects National Capital to rank among its top 20 hospitals by revenue and profitability and to be earnings-per-share accretive within the first 12 months, while keeping group leverage within its target of less than 2.5 times, underscoring the deal’s significance for Ramsay’s growth in key therapeutic areas and strengthening its presence in an attractive catchment area, subject to competition approval and completion expected in 2026.
The most recent analyst rating on (AU:RHC) stock is a Hold with a A$34.80 price target. To see the full list of analyst forecasts on Ramsay Health Care stock, see the AU:RHC Stock Forecast page.
Ramsay Health Care Limited has announced a change in the interest of its director, Natalie Davis, with an increase in her direct interest in the company’s securities. The change involves the acquisition of 74,075 Performance Rights under the company’s Equity Incentive Plan, bringing her total to 131,547 Performance Rights. This move reflects the company’s ongoing commitment to aligning its leadership’s interests with its long-term strategic goals, potentially impacting its market positioning and stakeholder confidence.
The most recent analyst rating on (AU:RHC) stock is a Hold with a A$34.80 price target. To see the full list of analyst forecasts on Ramsay Health Care stock, see the AU:RHC Stock Forecast page.
Ramsay Health Care Limited has announced the issuance of 39,918 performance rights as part of an employee incentive scheme. These securities are unquoted and are not intended to be listed on the ASX, reflecting the company’s strategy to incentivize and retain its workforce, which could enhance operational performance and stakeholder value.
The most recent analyst rating on (AU:RHC) stock is a Hold with a A$34.80 price target. To see the full list of analyst forecasts on Ramsay Health Care stock, see the AU:RHC Stock Forecast page.
Ramsay Health Care has announced a change in the director’s interest, specifically concerning Natalie Davis. On November 26, 2025, Davis acquired 21,071 Restricted Ordinary Shares as part of her FY25 short-term incentive award, increasing her indirect interest in the company. This acquisition reflects the company’s ongoing commitment to aligning executive incentives with shareholder interests, potentially impacting stakeholder confidence and market perception positively.
The most recent analyst rating on (AU:RHC) stock is a Hold with a A$34.80 price target. To see the full list of analyst forecasts on Ramsay Health Care stock, see the AU:RHC Stock Forecast page.
At the 2025 Annual General Meeting, Ramsay Health Care announced the successful passing of all resolutions, including the re-election of key directors and the approval of performance rights for the Managing Director. These decisions reflect strong shareholder support and are likely to reinforce the company’s leadership and strategic direction, potentially impacting its market position and stakeholder confidence positively.
The most recent analyst rating on (AU:RHC) stock is a Hold with a A$33.00 price target. To see the full list of analyst forecasts on Ramsay Health Care stock, see the AU:RHC Stock Forecast page.
Ramsay Health Care’s 2025 AGM highlighted the company’s strategic focus on navigating industry challenges, with a renewed emphasis on its core Australian business. Despite facing cost pressures and industry headwinds, the company is optimistic about its refreshed strategy and leadership under new CEO Natalie Davis. Ramsay reported a 1.7% increase in underlying net profit after tax, driven by strong performance in its Australian and UK hospital businesses, although earnings from its UK mental health care business, Elysium, and Ramsay Santé were lower.
The most recent analyst rating on (AU:RHC) stock is a Hold with a A$33.00 price target. To see the full list of analyst forecasts on Ramsay Health Care stock, see the AU:RHC Stock Forecast page.
Ramsay Health Care has appointed Anthony Neilson as the new Group Chief Financial Officer, effective November 24, 2025. Neilson brings over 30 years of experience in finance and commercial roles, having previously worked at Santos Ltd and Roc Oil Ltd. His expertise in mergers, acquisitions, and capital management is expected to strengthen Ramsay’s leadership team and accelerate its transformation efforts, ultimately improving performance and returns on capital.
The most recent analyst rating on (AU:RHC) stock is a Hold with a A$35.90 price target. To see the full list of analyst forecasts on Ramsay Health Care stock, see the AU:RHC Stock Forecast page.
Ramsay Santé, a subsidiary of Ramsay Health Care, reported a 2.6% increase in revenue and a 6.5% rise in EBITDA for the quarter ending September 2025, despite challenges such as reduced public funding and cost inflation. The company’s strong performance, particularly in Sweden, was driven by activity growth, cost control measures, and strategic expansions, including new care models and facilities in France and Norway, which align with patient needs and enhance healthcare service quality.
The most recent analyst rating on (AU:RHC) stock is a Hold with a A$33.00 price target. To see the full list of analyst forecasts on Ramsay Health Care stock, see the AU:RHC Stock Forecast page.
Ramsay Health Care Limited has announced a new dividend distribution for its security holders, with a distribution amount of AUD 2.9642 per unit. The payment is scheduled for April 20, 2026, and pertains to a six-month period ending on April 19, 2026. This announcement reflects the company’s ongoing commitment to providing returns to its investors and may influence its market positioning by demonstrating financial stability and shareholder value.
The most recent analyst rating on (AU:RHC) stock is a Hold with a A$33.00 price target. To see the full list of analyst forecasts on Ramsay Health Care stock, see the AU:RHC Stock Forecast page.
Ramsay Health Care has issued a correction to its 2025 Annual Report concerning inaccuracies in the tables listing the top 20 ordinary shareholders and CARES holders. The correction involves the names and order of these shareholders, which were previously incorrect. This update ensures transparency and accuracy in shareholder information, which is crucial for maintaining investor trust and compliance with reporting standards.
The most recent analyst rating on (AU:RHC) stock is a Hold with a A$37.00 price target. To see the full list of analyst forecasts on Ramsay Health Care stock, see the AU:RHC Stock Forecast page.
Ramsay Health Care Limited announced the cessation of several performance rights, totaling 199,893 securities, due to unmet conditions. This development could impact the company’s financial strategies and stakeholder expectations, as performance rights are often linked to employee incentives and company performance metrics.
The most recent analyst rating on (AU:RHC) stock is a Hold with a A$32.00 price target. To see the full list of analyst forecasts on Ramsay Health Care stock, see the AU:RHC Stock Forecast page.